Top 5 High Dividend Companies To Own In Right Now

Top 5 High Dividend Companies To Own In Right Now: OXiGENE Inc.(OXGN)

OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics to treat cancer and eye diseases in the United States. It primarily focuses on the development of vascular disrupting agents (VDAs) that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, as well as associate with visual impairment in various ophthalmological diseases and conditions. The company?s products include ZYBRESTAT, which is in fosbretabulin in anaplastic cancer of the thyroid (FACT) trial?Phase 2/3 study for the treatment of anaplastic thyroid cancer; in fosbretabulin in advanced lung oncology (FALCON) trial?Phase 2 randomized and controlled study to treat non-small cell lung cancer; in Phase 2 Simon two-stage design study for the treatment of platinum-resistant ovarian cancer; and in Phase 2 randomized controlled study to treat platinum-relapsed but platinum sensitive ovarian cancer. Its products also comprise OXi4503 that is in Phase 1 dose-escalation study for the treatment of acute myelogenous leukemia and myelodysplastic syndromes; Phase 1b dose-ranging study to treat solid tumors with hepatic tumor burden; and Phase 1 dose-escalation study for the treatment of refractory solid tumors. In addition, the company?s products consist of ZYBRESTAT, which is in Phase 2 randomized, double-masked, placebo-controlled, single-dose study for proof-of-mechanism study in polypoidal choroidal vasculopathy. OXiGENE has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology, and OXi4503. The company was founded in 1988 and is headquartered in South San Francisco, California.

Advisors' Opinion:

• [By Bryan Murphy]

  If you missed the recent surges from Neurometrix Inc. (NASDAQ:NURO) and/or OXiGENE Inc. (NASDAQ:OXGN), and decided to skip an entry on either or both becaus! e they were too frothy at the time, then here's some good news.... you're getting a second chance. Both NURO and OXGN are getting their proverbial second wind, and they're doing so at a price much lower than the price you would have had to pay for either just a few days ago. There's just one catch - you may want to hurry of you want in. This second wind is unfurling as rapidly as the first surges did.

• [By Bryan Murphy]

  In the very short run, OXiGENE Inc. (NASDAQ:OXGN) is overbought and probably due for a setback, not unlike the all the other one-day surges and subsequent pullbacks we've seen from the stock since February of this year. Today's pop from OXGN, however, is quite different than all the rest... this time, it's got a legitimate shot at following through on the upside effort. Ergo, this little biopharma name is actually one of the market's best 'trades' right now.

• [By Wallace Witkowski]

  Shares of Oxigene Inc. (OXGN) more than doubled on very heavy volume after the microcap biotech said a mid-stage study of its drug Zybrestat, when used with Roches Avastin, showed increased survival in ovarian cancer patients. Oxigene shares rallied 129% to $5.55 , and were one of the most heavily traded issues after hours with more than 4.2 million shares exchanging hands.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-5-high-dividend-companies-to-own-in-right-now.html